Adrian Haigh Sells 22,222 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $10.30, for a total value of $228,886.60. Following the completion of the sale, the chief operating officer now owns 22,222 shares of the company’s stock, valued at $228,886.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Adrian Haigh also recently made the following trade(s):

• On Wednesday, April 17th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.91, for a total transaction of $220,220.02.

Fennec Pharmaceuticals Stock Down 1.3 %

NASDAQ:FENC opened at $9.57 on Friday. The firm has a 50 day moving average of $10.10 and a 200 day moving average of $9.33. Fennec Pharmaceuticals Inc has a 52 week low of $6.30 and a 52 week high of $11.92. The stock has a market capitalization of $259.35 million, a price-to-earnings ratio of -15.69 and a beta of 0.38.

Fennec Pharmaceuticals (NASDAQ:FENC) last issued its earnings results on Thursday, March 21st. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The firm had revenue of $9.74 million during the quarter, compared to analysts’ expectations of $9.47 million. As a group, analysts expect that Fennec Pharmaceuticals Inc will post 0.11 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on FENC shares. HC Wainwright boosted their price objective on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Thursday, April 4th. Craig Hallum boosted their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. Finally, Wedbush restated an “outperform” rating and set a $16.00 price objective on shares of Fennec Pharmaceuticals in a research note on Monday, March 18th.

Institutional Investors Weigh In On Fennec Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada lifted its stake in shares of Fennec Pharmaceuticals by 21.1% in the 4th quarter. Royal Bank of Canada now owns 7,102 shares of the company’s stock valued at $79,000 after purchasing an additional 1,236 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Fennec Pharmaceuticals by 107.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock worth $34,000 after acquiring an additional 1,578 shares during the period. Citigroup Inc. boosted its stake in shares of Fennec Pharmaceuticals by 10.3% during the 1st quarter. Citigroup Inc. now owns 18,590 shares of the company’s stock worth $151,000 after acquiring an additional 1,742 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Fennec Pharmaceuticals by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 81,768 shares of the company’s stock valued at $614,000 after acquiring an additional 1,895 shares during the period. Finally, Hartford Financial Management Inc. increased its stake in shares of Fennec Pharmaceuticals by 4.4% in the 4th quarter. Hartford Financial Management Inc. now owns 47,348 shares of the company’s stock valued at $531,000 after purchasing an additional 2,000 shares in the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.